[{"id":"877f9753-ad0d-4d88-acac-f4bc15a1871f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01265901","created_at":"2021-06-30T14:52:33.364Z","updated_at":"2024-07-02T16:37:17.142Z","phase":"Phase 3","brief_title":"IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT01265901","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • cyclophosphamide • IMA-901 • Leukine (sargramostim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 339","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2017-10-12"}]